Skip to main content

Table 3 Prediction model and risk score calculation

From: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Risk Factor

HR

95% CI

P value

Assigned score

Absence of AEa in first 4 weeks

1.60

(1.22, 2.11)

0.001

2

> 2 metastasis sites

1.62

(1.21, 2.17)

0.001

2

ECOG PS > 0

2.48

(1.70, 3.61)

< 0.001

3

  1. HR hazard ratio, CI confidence interval, AE adverse event, ECOG PS Eastern Cooperative Oncology Group performance status
  2. aAdverse events (AE) are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment